The relation between percentage of immunostained cells and amplification status in breast cancers with equivocal result for Her2 immunohistochemistry
| Autor: | Paul J. Zhang, Onder Onguru |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty Databases Factual Receptor ErbB-2 Cell Breast Neoplasms Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine Breast cancer medicine Humans Equivocal result skin and connective tissue diseases In Situ Hybridization Fluorescence business.industry Incidence (epidemiology) Gene Amplification Cell Biology medicine.disease Immunohistochemistry Staining 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Fish Female business Immunostaining |
| Zdroj: | Pathology, research and practice. 212(5) |
| ISSN: | 1618-0631 |
| Popis: | We analyzed Her2 amplification in breast cancers with equivocal IHC staining to investigate the significance of percentage of Her2 immunostained tumor cells. We especially included the breast cancers with complete/incomplete membrane staining at moderate intensity in less than 10% of the invasive tumor cells. Of 1804 breast cases, 180 had moderate complete/incomplete membrane Her2 immunostaining. According to 2013 ASCO/CAP guideline, 124 were in IHC score 2+ and 56 in 1+ category. The percentage of Her2 immunostained invasive tumor cells were determined by visual estimation at the time of diagnosis and categorized into three groups;10%, 10-50%, and50% for this review. FISH was performed by dual DNA probe and data of Her2/cep17 ratio, Her2/cell and Cep17/cell were recorded applying 2013 ASCO/CAP criteria. There were 22 cases (12.2%) in50% group, 102 (56.7%) in 10-50% group, and 56 (31.1%) in10% group. Overall Her2 amplification was 25.5%. Her2 was amplified in 12 (54.5%) cases in50% group; 26 (25.4%) in 10-50% and 8 (14.3%) in10%. Her2 amplification was more frequent in cancers with50% moderately immunostained cells in IHC equivocal group. However, most of Her2 IHC equivocal breast cancers contain moderate amount (10-50%) of immunostained cells. Relatively small but non-neglectable number (14%) of cases in10% group was Her2 amplified by FISH which approaches to overall incidence of Her2 overexpression (15-20%) in all breast cancer. Breast cancers with moderate complete/incomplete membrane Her2 IHC staining in10% of invasive tumor cells should be regarded as equivocal and reflex FISH should be performed in these cases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect